Related Experiment Videos
Minimal disease detection and confirmation in hematologic malignancies: combining cell sorting with clonality
Barbara K Zehentner1, Wayne Fritschle, Tess Stelzer
1HematoLogics, Inc., Seattle, WA 98109, USA. Barbara@hematologics.com
Clinical Chemistry
|January 18, 2006
Summary
This study shows how flow cytometry and cell sorting combined with gene rearrangement profiling can detect minimal residual disease in leukemia and lymphoma. This method offers sensitive disease monitoring without needing custom primer design.
Area of Science:
- Hematology
- Molecular Biology
- Immunophenotyping
Background:
- Minimal residual disease (MRD) detection is crucial for leukemia and lymphoma management.
- Current methods may lack sensitivity or require extensive optimization.
Purpose of the Study:
- To demonstrate the technical application of combined flow cytometry, cell sorting, and gene rearrangement clonality profiling.
- To detect and confirm minimal disease in leukemia and lymphoma cases.
Main Methods:
- Flow cytometry identified abnormal lymphoid populations (0.05%-5%).
- Cell sorting purified these populations.
- Polymerase chain reaction (PCR) and capillary electrophoresis analyzed gene rearrangements in sorted and unsorted samples.
Main Results:
- Distinct clonality profiles confirmed tumor populations in sorted cells.
- Monoclonal signals were detected in sorted cells even when absent in unsorted samples with low abnormal cell percentages.
- The method successfully identified recurring leukemia cells in a follow-up sample.
Conclusions:
- Integrating flow cytometry, cell sorting, and gene rearrangement profiling enhances diagnostic certainty for aberrant cell populations.
- This strategy provides sensitive disease monitoring.
- It avoids the need for patient-specific primer design and assay optimization required for quantitative PCR.